Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.21 and has seen 0.84 million shares traded in the recent trading session. The company, currently valued at $239.31M, closed the recent trade at $0.94 per share which meant it lost -$0.06 on the day or -6.04% during that session. The ADAP stock price is -118.09% off its 52-week high price of $2.05 and 55.32% above the 52-week low of $0.42. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.88 million shares traded. The 3-month trading volume is 1.78 million shares.
The consensus among analysts is that Adaptimmune Therapeutics Plc ADR (ADAP) is Buy stock at the moment, with a recommendation rating of 1.80. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
Sporting -6.04% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the ADAP stock price touched $0.94 or saw a rise of 13.76%. Year-to-date, Adaptimmune Therapeutics Plc ADR shares have moved 18.02%, while the 5-day performance has seen it change -10.87%. Over the past 30 days, the shares of Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) have changed -20.01%. Short interest in the company has seen 6.83 million shares shorted with days to cover at 2.88.
Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 68.67% from the levels at last check today. The projected low price target is $1.0 while the price target rests at a high of $4.0. In that case, then, we find that the latest price level in today’s session is -325.53% off the targeted high while a plunge would see the stock gain -6.38% from the levels at last check today.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Figures show that Adaptimmune Therapeutics Plc ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -35.01% over the past 6 months, with this year growth rate of 61.90%, compared to 17.30% for the industry. Revenue growth from the last financial year stood is estimated to be 166.90%.
8 analysts offering their estimates for the company have set an average revenue estimate of 11.1M for the current quarter. 9 have an estimated revenue figure of 12.25M for the next ending quarter. Year-ago sales stood 7.32M and 231k respectively for this quarter and the next, and analysts expect sales will grow by 51.70% for the current quarter and 166.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.30% over the past 5 years. Earnings growth for 2024 is a modest 46.18% while over the next 5 years, the company’s earnings are expected to increase by 1.00%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is expected to release its next earnings report on 2024-Aug-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders
Insiders own 0.38% of the company shares, while shares held by institutions stand at 61.84% with a share float percentage of 62.08%. Investors are also buoyed by the number of investors in a company, with Adaptimmune Therapeutics Plc ADR having a total of 95.0 institutions that hold shares in the company. The top two institutional holders are MATRIX CAPITAL MANAGEMENT COMPANY, LP with over 38.97 million shares worth more than $38.0 million. As of 2024-06-30, MATRIX CAPITAL MANAGEMENT COMPANY, LP held 16.1135% of shares outstanding.
The other major institutional holder is ECOR1 CAPITAL, LLC, with the holding of over 27.4 million shares as of 2024-06-30. The firm’s total holdings are worth over $26.72 million and represent 11.3299% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Old Westbury Small & Mid Cap Strategies Fund and SPDR Portfolio Developed World ex-US ETF. As of Apr 30, 2024, the former fund manager holds about 0.58% shares in the company for having 1.49 shares of worth $1.4 million while later fund manager owns 246.31 shares of worth $0.23 million as of Aug 31, 2024, which makes it owner of about 0.10% of company’s outstanding stock.
